Brief: Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results And Provides An Update On Clinical Development Programs

Reata Pharmaceuticals

10/05/2022 11:43

May 10 (Reuters) - Reata Pharmaceuticals Inc  RETA.O :
    * REATA PHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2022
FINANCIAL RESULTS AND PROVIDES AN UPDATE ON CLINICAL DEVELOPMENT
PROGRAMS
    * Q1 NON-GAAP LOSS PER SHARE $1.33
    * Q1 GAAP LOSS PER SHARE $2.03
    * REAFFIRMS CASH RUNWAY THROUGH END OF 2024
    * UPDATES OUTCOME OF TYPE A MEETING WITH FDA ON PROTOCOL
AMENDMENT
FOR FALCON
    * REATA PHARMA - FALCON IS ENROLLING PATIENTS IN A BROAD
RANGE OF
AGES WITH AN ESTIMATED GLOMERULAR FILTRATION RATE BETWEEN 30 AND
90 ML/MIN/1.73 M
    * DIVISION STATED THAT PROPOSED PRIMARY ENDPOINT OF EGFR
CHANGE
FROM BASELINE AT WEEK 108  WAS REASONABLE
    * FDA ALSO CONFIRMED THAT, IF FALCON TRIAL IS POSITIVE, IT
COULD
SUPPORT REGISTRATION OF BARDOXOLONE IN ADPKD

Source text for Eikon:  ID:nBw1hQD7ra 
Further company coverage:  RETA.O 

 ((Reuters.Briefs@thomsonreuters.com;))